Eli Lilly (LLY) Operating Income Growth (5y) (2014 - 2026)

Eli Lilly (LLY) Operating Income Growth (5y) (2014 - 2026) Analysis & Trends

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 45.29%
Dec 31, 2025 29.26%
Sep 30, 2025 44.38%
Jun 30, 2025 37.31%
Mar 31, 2025 26.24%
Dec 31, 2024 28.03%
Sep 30, 2024 23.61%
Jun 30, 2024 20.49%
Mar 31, 2024 16.78%
Dec 31, 2023 16.17%
Sep 30, 2023 19.33%
Jun 30, 2023 6.88%
Mar 31, 2023 3.40%
Dec 31, 2022 11.12%
Sep 30, 2022 8.56%
Jun 30, 2022 5.71%
Mar 31, 2022 19.50%
Dec 31, 2021 17.45%
Sep 30, 2021 15.79%
Jun 30, 2021 8.07%